Cargando…

Evaluating the Cellular Targets of Anti-4-1BB Agonist Antibody during Immunotherapy of a Pre-Established Tumor in Mice

BACKGROUND: Manipulation of the immune system represents a promising avenue for cancer therapy. Rational advances in immunotherapy of cancer will require an understanding of the precise correlates of protection. Agonistic antibodies against the tumor necrosis factor receptor family member 4-1BB are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Gloria H. Y., Liu, Yuanqing, Ambagala, Thanuja, Kwon, Byoung S., Ohashi, Pamela S., Watts, Tania H.
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2882368/ https://www.ncbi.nlm.nih.gov/pubmed/20543982 http://dx.doi.org/10.1371/journal.pone.0011003

Ejemplares similares

Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity
por: Qi, Xinyue, et al.
Publicado: (2019)

Eomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy
por: Song, Chang, et al.
Publicado: (2014)

The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
por: Claus, Christina, et al.
Publicado: (2023)

Exposure of a Distinct PDCA-1(+) (CD317) B Cell Population to Agonistic Anti-4-1BB (CD137) Inhibits T and B Cell Responses Both In Vitro and In Vivo
por: Vinay, Dass S., et al.
Publicado: (2012)

4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity
por: Bartkowiak, Todd, et al.
Publicado: (2015)

Carcinoembryonic Antigen (CEA)-Specific 4-1BB-Costimulation Induced by CEA-Targeted 4-1BB-Agonistic Trimerbodies
por: Mikkelsen, Kasper, et al.
Publicado: (2019)

Agonistic 4-1bb antibodies in combination with inhibitory antibodies against CTLA-4, PD-L1 or LAG-3 ACT on CD8+ T cells in the tumor microenvironment and synergize to promote regression of established tumors
por: Horton, Brendan, et al.
Publicado: (2014)

4-1BB agonism: adding the accelerator to cancer immunotherapy
por: Chester, Cariad, et al.
Publicado: (2016)

4-1BB: A promising target for cancer immunotherapy
por: Kim, Alyssa Min Jung, et al.
Publicado: (2022)

Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy
por: Salomon, Ran, et al.
Publicado: (2022)

PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody
por: Escuin-Ordinas, Helena, et al.
Publicado: (2013)

4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy
por: Vinay, Dass S., et al.
Publicado: (2014)

Targeting 4-1BB for tumor immunotherapy from bench to bedside
por: Wang, Ya-Tao, et al.
Publicado: (2022)

A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity
por: Compte, Marta, et al.
Publicado: (2018)

A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity
por: Cheng, Lian-sheng, et al.
Publicado: (2022)

First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors
por: Hamid, Omid, et al.
Publicado: (2022)

Loss of the signaling adaptor TRAF1 causes CD8(+) T cell dysregulation during human and murine chronic infection
por: Wang, Chao, et al.
Publicado: (2012)

Higgs to bb in ATLAS
por: Lee, J S H
Publicado: (2013)

Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer
por: Sandin, Linda C, et al.
Publicado: (2014)

Pre-clinical development of the human CD40 agonistic antibody ADC-1013
por: Norlén, Per, et al.
Publicado: (2015)

Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy
por: Huang, Michael A., et al.
Publicado: (2015)

4-1BB Signaling Breaks the Tolerance of Maternal CD8(+) T Cells That Are Reactive with Alloantigens
por: Kim, Kwang H., et al.
Publicado: (2012)

ADC-1013, an agonistic CD40 antibody optimized for local immunotherapy of cancer
por: Mangsbo, Sara M, et al.
Publicado: (2013)

Search for the radion decay into a Higgs boson pair with $\gamma\gamma +bb, \tau\tau+bb$ and $bb+bb$ final states
por: Gennai, Simone
Publicado: (2004)

Phenomenology of BB.bar. Interactions
por: Miettinen, H
Publicado: (1974)

Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity
por: Hangiu, Oana, et al.
Publicado: (2022)

T-cell agonists in cancer immunotherapy
por: Choi, Yeonjoo, et al.
Publicado: (2020)

bbH
por: Asawatangtrakuldee, Chayanit
Publicado: (2022)

New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis
por: Etxeberria, Iñaki, et al.
Publicado: (2020)

Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy
por: Liu, Guizhong, et al.
Publicado: (2023)

CD28-independent, TRAF2-dependent Costimulation of Resting T Cells by 4-1BB Ligand
por: Saoulli, Katina, et al.
Publicado: (1998)

Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy
por: Kirtland, Max E., et al.
Publicado: (2020)

DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity
por: Muik, Alexander, et al.
Publicado: (2022)

Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy
por: Shrimali, Rajeev, et al.
Publicado: (2017)

NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy
por: Wang, Wei, et al.
Publicado: (2015)

Galectin-9 controls the therapeutic activity of 4-1BB–targeting antibodies
por: Madireddi, Shravan, et al.
Publicado: (2014)

A NOVEL MSLN×4-1BB BISPECIFIC ANTIBODY FOR SOLID TUMOR
por: Cheng, Liansheng, et al.
Publicado: (2023)

Correction: DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity
Publicado: (2022)

The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas.
por: Velders, M. P., et al.
Publicado: (1998)

Natural Killer Cell Mediated Antibody-Dependent Cellular Cytotoxicity in Tumor Immunotherapy with Therapeutic Antibodies
por: Seidel, Ursula J. E., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ckf14oe3ofe7cjlh0uo1ifn5el